Preparation and Evaluation of Sulfacetamide Sodium Ocusert for Controlled Drug Delivery
The intent of this research was to formulate and evaluate controlled release ocusert of sulfacetamide sodium for the treatment of bacterial conjunctivitis. Ocusert is a sterile preparation having drug as dispersion or as solution in the polymeric base. Prepared Ocuserts were formulated using hydroxyl propyl methyl cellulose K-15 and Ethyl cellulose as polymers at various concentrations and combinations. Polymeric Films were prepared by mercury casting method using different ratios of polymers. Selected physiochemical properties such as thickness, weight, percentage moisture absorption, and in-vitro release and sterility studies of sulfacetamide sodium ocusert were studied and reported that prepared ocusert resolved the problems of poor bioavailability, frequent dosing and wastage of active ingredient.
Keywords: Hydroxypropyl methyl cellulose K-15, ocusert, sulfacetamide sodium
2. Azari A.A and Barney N.P. Conjunctivitis: A Systematic Review of Diagnosis and Treatment, JAMA, 2013; 310(16): 1721-1729.
3. Nageswara Rao. G, Rama Krishna. A. Formulation design and in-vitro evaluation of natamycin ocular insert, Ijprbs, 2014; 3(2): 687-695.
4. Singh A, Negi D, Mishra N, Baldi A. Recent trends in ocular drug delivery, Pharmaspire, 2018; 10(2): 55-63.
5. Rathore KS, Nema RK. Review on Ocular Inserts, Int. J. Pharm Tech Res, 2009; 1(2): 1-5.
6. Dave V, Palival S, Yadav S. Formulation and evaluation of controlled delivery of aceclofenac through ocular insert, Turk. J. Pharm. Sci, 2013; 10 (2): 205-220.
7. Fair RJ and Tor Y. Antibiotics and Bacterial Resistance in the 21st Century, Perspect Medicin Chem, 2014; 6: 25-64.
8. Suja C, Vinshia J and Mageswari S.S.U. Bacterial and Fungal Profile of External Ocular Infections in a Tertiary Care Hospital, Int.J.Curr.Microbiol.App.Sci., 2019; 8(2): 2081-2089.
9. Leopold IH. Anti-Infective Agents. Pharmacology of the Eyes. Chapter 9, Part of the Handbook of Experimental Pharmacology. Springer-Verlag Berlin Heidelberg. 2015; 69: 385-457.
10. Villa DE, Aguilar MR and Rojo L. Folic acid antagonists: Antimicrobial and Immuno-modulating mechanisms and applications, Int J Mol Sci, 2019; 20(20): 4996-5002.
11. Igwe C.N and Okoro U.C. Synthesis, Characterization, and Evaluation for Antibacterial and Antifungal Activities of N-Heteroaryl Substituted Benzene Sulphonamides, Organic Chemistry International, 2014; 2014: 1-5.
12. Patel GM and Patel MM. Recent advances and challenges in ocular drug delivery system, Pharma Times, 2007; 39: 21-25.
13. Paul S, Kumar G, Kothiyal P. Design and evaluation of soluble ocular drug insert for controlled release of acyclovir, Int. J. Drug Res. Tech, 2012; 2(5): 393-398.
14. Saritha A, Anuradha M S. Design and evaluation of moxifloxacin poly vinyl alcohol occular films, Int. J. Curr.Res.Chem.Pharma.Sci, 2015; 2(5): 29-34.
15. Baeyens V, Kaltsatos V, Boisrame B, Varesio E. Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections, J. of Cont. Release, 1997; 52: 215-220.
16. Pillai S, Abhilash S, Panneerselvam1 T, Muneer T, Shabaraya A. Design and evaluation of timolol maleate ocuserts, Research in Pharmacy, 2011; 1(2): 13-16.
17. Seth M, Kumar Sahoo S, Ranjan Pani N. Optimization of polymers in piroxicam ocusert: in-vitro and invivo study, Biopharm. Journal, 2015; 1(2): 71‐80.
18. Kaul S, Kumar G, Kothiyal P. Design and evaluation of soluble ocular drug insert for controlled release of acyclovir, Int. J. Drug Res. Tech, 2012; 2(5): 393-398.
19. Khar RK and Vyas SP. Targeted and controlled drug-delivery novel carrier systems, 1st edition. CBS Publishers and Distributors, New Delhi; 2002: 384.
20. Sultana Y, Aquil M, Ali A. Ocular insert for controlled delivery of pefloxacin mesylate: preparation and evaluation, Acta Pharma, 2005; 55: 305-314.
21. Rastogi SK, Vaya N, Mishra B. Ophthamic inserts: An overview, The Eastern Pharmacist, 1996; 2: 41-44.
22. Rathore KS, Kumar R, Sisodia S. Timolol maleate a gol standard drug in glaucoma used as ocular films and inserts: an overview, Int. J. of Pharm. Sci. Rev. and Res, 2010; 3 (1): 23-29.
23. Ros F.E, Greve E.L, Dake C.L, Miller W.M. Experiences with Ocusert, Amsterdam, 1976: 43-44.
24. Priya KRN, Bhattacharyya S and Babu R, Formulation and Evaluation of Erodible Ocular Films of Valacyclovir Hydrochloride Department of Pharmaceutics, Dhaka Univ. J. Pharm. Sci. 2014; 13(1): 75-81.
25. Jeganath S, Ashlin Viji V, Sheeja Devi K, Jayachandran D. L, Krishnamoorthy M. Rao. Design and evaluation of controlled release ocuserts of indomethacin, Int. J. of Pharm. & Pharm. Sci. Res, 2011; 1(2): 80-86.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).